Trials / Completed
CompletedNCT01240161
Personalized Translational Platform for Biomarker Discovery in Brain Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 37 (actual)
- Sponsor
- Marcelo F. Di Carli, MD, FACC · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT | Each patient will have 0-3 or more FLT-PET brain scans. |
Timeline
- Start date
- 2009-12-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2010-11-15
- Last updated
- 2017-08-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01240161. Inclusion in this directory is not an endorsement.